Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Thomas B. G. Poulsen, Azra Karamehmedovic, Christopher Aboo, Malene Møller Jørgensen, Xiaobo Yu, Xiangdong Fang, Jonathan M. Blackburn, Claus H. Nielsen, Tue W. Kragstrup & Allan Stensballe. (2020) Protein array-based companion diagnostics in precision medicine. Expert Review of Molecular Diagnostics 20:12, pages 1183-1198.
Read now
Read now
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer & Erika Vacchelli. (2020) Trial watch: IDO inhibitors in cancer therapy. OncoImmunology 9:1.
Read now
Read now
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer & Erika Vacchelli. (2020) Trial watch: TLR3 agonists in cancer therapy. OncoImmunology 9:1.
Read now
Read now
Articles from other publishers (37)
Kuin Tian Pang, Yuan Sheng Yang, Wei Zhang, Ying Swan Ho, Pietro Sormanni, Thomas C.T. Michaels, Ian Walsh & Sean Chia. (2023) Understanding and controlling the molecular mechanisms of protein aggregation in mAb therapeutics. Biotechnology Advances 67, pages 108192.
Crossref
Crossref
Andrea Di Ianni, Luca Barbero, Tiziana Fraone, Kyra Cowan & Federico Riccardi Sirtori. (2023) Preclinical risk assessment strategy to mitigate the T-cell dependent immunogenicity of protein biotherapeutics: State of the art, challenges and future perspectives. Journal of Pharmaceutical and Biomedical Analysis 234, pages 115500.
Crossref
Crossref
Dongxue Liu, Linlin Hu & Hua Shao. (2023) Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers. Cancer Chemotherapy and Pharmacology 92:3, pages 165-179.
Crossref
Crossref
Michael Hwang, Yen Lin Chia, Yanan Zheng, Cecil Chi‐Keung Chen, Jimmy He, Xuyang Song, Diansong Zhou, Sarah B. Goldberg, Lillian L. Siu, David Planchard, Solange Peters, Helen Mann, Lee Krug & Caroline Even. (2022) Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time‐varying clearance. British Journal of Clinical Pharmacology 89:5, pages 1601-1616.
Crossref
Crossref
Su Jong Yu. (2023) Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. Pharmacology & Therapeutics 244, pages 108387.
Crossref
Crossref
Shusuke Kawashima & Yosuke Togashi. (2022) Resistance to immune checkpoint inhibitors and the tumor microenvironment. Experimental Dermatology 32:3, pages 240-249.
Crossref
Crossref
Diana Rafael, Sara Montero, Pilar Carcavilla, Fernanda Andrade, Júlia German-Cortés, Zamira V. Diaz-Riascos, Joaquin Seras-Franzoso, Monserrat Llaguno, Begoña Fernández, Alfredo Pereira, Esteban F. Duran-Lara, Simó SchwartzJr.Jr. & Ibane Abasolo. (2023)
Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong
In Vitro
and
In Vivo
Anti-Tumorigenic Activity in Kirsten Rat Sarcoma-Mutated Cancers
. ACS Applied Materials & Interfaces.
Crossref
Crossref
Chan Kim, Hannah Yang, Ilhwan Kim, Beodeul Kang, Hyeyeong Kim, Hyunho Kim, Won Suk Lee, Sanghoon Jung, Ho Yeong Lim, Jaekyung Cheon & Hong Jae Chon. (2022) Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma. JAMA Oncology 8:12, pages 1825.
Crossref
Crossref
Xuanyu Zhu, Longfei Zhu & Yan Wu. (2022) Manipulating Metabolic Alterations and their Consequences to Unleash the Potential of Antitumor Immunotherapy. Current Protein & Peptide Science 23:9, pages 585-601.
Crossref
Crossref
Choong-kun Lee, Stephen L. Chan & Hong Jae Chon. (2022) Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?. Cancers 14:13, pages 3213.
Crossref
Crossref
Romy Mosch & Henk-Jan Guchelaar. (2022) Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients. Frontiers in Immunology 13.
Crossref
Crossref
Miguel Borregón, Katherine Martínez, Alba Ramos, Irene Ramos, Beatriz Berzal, Manuel Mazariegos, Elia Martínez, Tatiana Hernández, Bernard Doger & Víctor Moreno. (2022) Anti-drug antibodies in the current management of cancer. Cancer Chemotherapy and Pharmacology 89:5, pages 577-584.
Crossref
Crossref
Lihua Du, Haozhe He, Zecong Xiao, Hong Xiao, Yongcheng An, Huihai Zhong, Minzhao Lin, Xiaochun Meng, Shisong Han & Xintao Shuai. (2022) GSH‐Responsive Metal–Organic Framework for Intratumoral Release of NO and IDO Inhibitor to Enhance Antitumor Immunotherapy. Small, pages 2107732.
Crossref
Crossref
Clémence Marin, Nihel Khoudour, Aurélien Millet, Dorothée Lebert, Pauline Bros, Fabienne Thomas, David Ternant, Bruno Lacarelle, Jérôme Guitton, Joseph Ciccolini & Benoit Blanchet. (2021) Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. Pharmaceuticals 14:8, pages 796.
Crossref
Crossref
Yawen Dong, Jeffrey Sum Lung Wong, Ryohichi Sugimura, Ka-On Lam, Bryan Li, Gerry Gin Wai Kwok, Roland Leung, Joanne Wing Yan Chiu, Tan To Cheung & Thomas Yau. (2021) Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. Cancers 13:8, pages 1949.
Crossref
Crossref
Etienne Chatelut, Jeroen J. M. A. Hendrikx, Jennifer Martin, Joseph Ciccolini & Dirk Jan A. R. Moes. (2021) Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. Pharmacology Research & Perspectives 9:2.
Crossref
Crossref
Jwala Sivaccumar, Annamaria Sandomenico, Luigi Vitagliano & Menotti Ruvo. (2021) Monoclonal Antibodies: A Prospective and Retrospective View. Current Medicinal Chemistry 28:3, pages 435-471.
Crossref
Crossref
Nkiruka Ibeanu, Raphael Egbu, Lesley Onyekuru, Hoda Javaheri, Peng Tee Khaw, Gareth R. Williams, Steve Brocchini & Sahar Awwad. (2020) Injectables and Depots to Prolong Drug Action of Proteins and Peptides. Pharmaceutics 12:10, pages 999.
Crossref
Crossref
Mohamed Hassanein, Michael A Partridge, Weiping Shao & Albert Torri. (2020) Assessment of clinically relevant immunogenicity for mAbs; are we over reporting ADA?. Bioanalysis 12:18, pages 1325-1336.
Crossref
Crossref
Anna Vaisman-Mentesh, Matias Gutierrez-Gonzalez, Brandon J. DeKosky & Yariv Wine. (2020) The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies. Frontiers in Immunology 11.
Crossref
Crossref
Ngoc B. Pham & Wilson S. Meng. (2020) Protein aggregation and immunogenicity of biotherapeutics. International Journal of Pharmaceutics 585, pages 119523.
Crossref
Crossref
Kartik Sehgal, Daniel B. Costa & Deepa Rangachari. (2020) Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?. Frontiers in Oncology 10.
Crossref
Crossref
Shazia K. Nakhoda & Anthony J. Olszanski. (2020) Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. Pharmaceutical Medicine 34:2, pages 83-91.
Crossref
Crossref
Aude Desnoyer, Sophie Broutin, Julia Delahousse, Christophe Maritaz, Louis Blondel, Olivier Mir, Nathalie Chaput & Angelo Paci. (2020) Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies. European Journal of Cancer 128, pages 119-128.
Crossref
Crossref
Diego Enrico, Angelo Paci, Nathalie Chaput, Eleni Karamouza & Benjamin Besse. (2020) Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?. Clinical Cancer Research 26:4, pages 787-792.
Crossref
Crossref
Qihui Zhou, Nikola Mareljic, Meike Michaelsen, Samira Parhizkar, Steffanie Heindl, Brigitte Nuscher, Daniel Farny, Mareike Czuppa, Carina Schludi, Alexander Graf, Stefan Krebs, Helmut Blum, Regina Feederle, Stefan Roth, Christian Haass, Thomas Arzberger, Arthur Liesz & Dieter Edbauer. (2019)
Active poly‐GA vaccination prevents microglia activation and motor deficits in a
C9orf72
mouse model
. EMBO Molecular Medicine 12:2.
Crossref
Crossref
Lisa Kötzner, Bayard Huck, Sakshi Garg & Klaus Urbahns. 2020.
1
62
.
Bernhard Kratzer, Sandra Hofer, Maja Zabel & Winfried F. Pickl. (2019) All the small things: How virus‐like particles and liposomes modulate allergic immune responses. European Journal of Immunology 50:1, pages 17-32.
Crossref
Crossref
Marcia Stickler, Anita Reddy, Joanna M Xiong, Melanie H Wong, Yoshiko Akamatsu, Paul R Hinton & Fiona A Harding. (2019) Design, creation and in vitro testing of a reduced immunogenicity humanized anti-CD25 monoclonal antibody that retains functional activity. Protein Engineering, Design and Selection 32:12, pages 543-554.
Crossref
Crossref
Jasmine Davda, Paul Declerck, Siwen Hu-Lieskovan, Timothy P. Hickling, Ira A. Jacobs, Jeffrey Chou, Shahram Salek-Ardakani & Eugenia Kraynov. (2019) Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
David Ternant & Stéphanie Chhun. (2020) Variabilité pharmacocinétique des anticorps thérapeutiques. médecine/sciences 35:12, pages 1130-1136.
Crossref
Crossref
Kasper Bendix Johnsen, Annette Burkhart, Louiza Bohn Thomsen, Thomas Lars Andresen & Torben Moos. (2019) Targeting the transferrin receptor for brain drug delivery. Progress in Neurobiology 181, pages 101665.
Crossref
Crossref
Lucas Gonzalez-Nieto, Isabelle M. Castro, Georg F. Bischof, Young C. Shin, Michael J. Ricciardi, Varian K. Bailey, Christine M. Dang, Nuria Pedreño-Lopez, Diogo M. Magnani, Keisuke Ejima, David B. Allison, Hwi Min Gil, David T. Evans, Eva G. Rakasz, Jeffrey D. Lifson, Ronald C. Desrosiers & Mauricio A. Martins. (2019) Vaccine protection against rectal acquisition of SIVmac239 in rhesus macaques. PLOS Pathogens 15:9, pages e1008015.
Crossref
Crossref
Sophie Tourdot & Timothy P Hickling. (2019) Nonclinical immunogenicity risk assessment of therapeutic proteins. Bioanalysis 11:17, pages 1631-1643.
Crossref
Crossref
Bassel Nazha, Manoj Mishra, Rebecca Pentz & Taofeek K. Owonikoko. (2019) Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy. American Society of Clinical Oncology Educational Book:39, pages 3-10.
Crossref
Crossref
Hugh C. Welles, Madeleine F. Jennewein, Rosemarie D. Mason, Sandeep Narpala, Lingshu Wang, Cheng Cheng, Yi Zhang, John-Paul Todd, Jeffrey D. Lifson, Alejandro B. Balazs, Galit Alter, Adrian B. McDermott, John R. Mascola & Mario Roederer. (2018) Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. PLOS Pathogens 14:12, pages e1007395.
Crossref
Crossref
Ronit Mazor, Emily King & Ira Pastan. (2018) Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1. Cellular Immunology 334, pages 38-41.
Crossref
Crossref